Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Jade Biosciences, Inc. (JBIO) had Normalized Income after Taxes of $-32.13M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-32.13M |
|
-- |
|
-- |
|
$27.78M |
|
$-27.78M |
|
$-4.36M |
|
$-32.13M |
|
$-32.13M |
|
$-32.13M |
|
$-32.13M |
|
$-32.13M |
|
|
Normalized Income after Taxes |
$-32.13M |
$-27.78M |
|
$-27.55M |
|
28.43M |
|
28.43M |
|
$-0.86 |
|
$-0.86 |
|
| Balance Sheet Financials | |
$222.98M |
|
$0.15M |
|
$0.98M |
|
$223.97M |
|
$21.62M |
|
-- |
|
$0.79M |
|
$22.41M |
|
$201.55M |
|
$201.56M |
|
$201.56M |
|
32.63M |
|
| Cash Flow Statement Financials | |
$-38.92M |
|
$-0.14M |
|
$190.61M |
|
$69.39M |
|
$220.94M |
|
$151.56M |
|
$6.32M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.31 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-39.05M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-15.94% |
|
-15.94% |
|
-14.35% |
|
-15.94% |
|
$6.18 |
|
$-1.37 |
|
$-1.37 |
|